FDA APPROVED FOR COLON
CANCER SCREENING

Coverage
& support

We are here to support you and your
patients with billing and claims

Order Shield

Shield™ is the only FDA-approved blood test for CRC screening with Medicare coverage

$0

out-of-pocket cost
for eligible Medicare Part B patients*

CMS covers the cost of a follow-up colonoscopy after a positive Shield test result

Shield is also covered for patients receiving Community Care, authorized by the Veterans Health Administration, and TRICARE

Eligible Medicare Fee for Service (FFS) patients will have $0 out-of-pocket cost for Shield. Patients with Medicare Advantage may be subject to co-pays, co-insurances, and deductibles, depending on their specific plan

CMS=Centers for Medicare and Medicaid Services.

*Medicare Advantage patients may be subject to co-pays, co-insurances, and deductibles, depending on their specific plan.

CMS covers the cost of a follow-up colonoscopy after a positive Shield test result

Shield is also covered for patients receiving Community Care, authorized by the Veterans Health Administration, and TRICARE

Eligible Medicare Fee for Service (FFS) patients will have $0 out-of-pocket cost for Shield. Patients with Medicare Advantage may be subject to co-pays, co-insurances, and deductibles, depending on their specific plan

CMS=Centers for Medicare and Medicaid Services.

*Medicare Advantage patients may be subject to co-pays, co-insurances, and deductibles, depending on their specific plan.

Patients not covered by Medicare may have an out-of-pocket cost

See details

97%

of PCPs who used Shield will continue to offer the blood test in their practice for CRC screening1*

*Internal data on file, November 2022

Revolutionize adherence in your practice

Start screening

Guardant Health is here to help

Dedicated support for practices and patients:

Billing-related
paperwork
Billing
questions
Claims and
appeals
Integrate the Shield test
into your practice

“I’ve had a lot of success getting patients to screen with Shield... The bottom line is you don’t have an excuse not to give your blood”

—
Yulia Koltzova-Rang, MD
Internal Medicine

Important Product Information

Intended Use

The Shield™ test is a qualitative, in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA from blood collected in the Guardant Shield Blood Collection Kit.
Shield is intended for colorectal cancer screening in individuals at average risk for the disease, age 45 years or older. Patients with a positive result should be followed by colonoscopy. Shield is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals. This test is performed at Guardant Health, Inc.

Precaution: Based on data from clinical studies, Shield has limited detection (55%-65%) of Stage I colorectal cancer and does not detect 87% of precancerous lesions. One out of 10 patients with a negative Shield result may have a precancer that would have been detected by a screening colonoscopy. Shield demonstrated high detection of Stages II, III, and IV colorectal cancer.

Limitations and Other Important Information: The Shield test is not intended for patients that have personal history of colorectal cancer, adenomas, or other related cancers; or those who had a positive result on another colorectal cancer screening method within the last six months, have been diagnosed with a condition associated with high risk for colorectal cancer such as Inflammatory Bowel Disease (IBD), chronic ulcerative colitis (CUC), Crohn’s disease; or who have a family history of colorectal cancer, or certain hereditary syndromes. Providers should discuss the most appropriate screening test to use with patients depending on their medical history and individual circumstances. Shield may produce a false negative or false positive result. A false negative result may occur when the Shield test does not detect a colorectal tumor signal while a colonoscopy identifies a colorectal cancer. A negative result does not guarantee the absence of colorectal cancer or advanced adenoma, and patients should continue participating in colorectal cancer screening programs at the appropriate guideline-recommended intervals. A false positive result may occur when the Shield test generates a positive result while a colonoscopy will not find colorectal cancer or advanced adenoma.

Please read our Provider Brochure for complete product information about the Shield test including full safety information.

  1. Reference:
  2. Data on file. Guardant Health, Inc.